	US 12,296,050 B2
	Pharmaceutical compositions comprising maralixibat and uses thereof
Parag Ved, Foster City, CA (US)
Assigned to MIRUM PHARMACEUTICALS, INC., Foster City, CA (US)
Filed by Mirum Pharmaceuticals, Inc., Foster City, CA (US)
Filed on Oct. 5, 2023, as Appl. No. 18/377,216.
Prior Publication US 2025/0114310 A1, Apr. 10, 2025
Int. Cl. A61K 9/20 (2006.01); A61K 31/4995 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01)

CPC A61K 9/2054 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2031 (2013.01); A61K 31/4995 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01)]

28 Claims

1. A pharmaceutical composition comprising maralixibat, or a pharmaceutically acceptable salt thereof, and:

(i) a diluent selected from the group consisting of dextrates, dextrin, dextrose, lactose, lactose monohydrate, mannitol, sorbitol, cellulose, modified celluloses, and any combination thereof;

(ii) a glidant selected from the group consisting of silicon dioxide, magnesium stearate, talc, and any combinations thereof;

(iii) a lubricant that is glyceryl palmitostearate in an amount of from about 6% to about 12% (w/w); and

(iv) a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, starch, sodium starch glycolate, and any combinations thereof in an amount of from about 1% to about 10% (w/w).